MUcociliary Clearance IN Stroke (MUCINS)
Status
Conditions
Treatments
Details and patient eligibility
About
Stroke patients frequently suffer from stroke associated pneumonia. Pathophysiologically speaking, dysphagia and central nervous system (CNS)-injury induced immunosuppression largely contribute to the risk for pneumonia. In mouse models for stroke, the self-cleaning mechanisms of the lung are also affected by stroke, possibly further contributing to this risk.
The investigators designed a pilot-study to examine the structural and functional integrity of the self-cleaning mechanisms of the lung in stroke patients.
Full description
Survival and functional outcome of stroke is strongly depending on the occurence of pneumonia (stroke-associated pneumonia, SAP). Early diagnose and treatment of SAP is paramount in the treatment of stroke patients. While dysphagia strongly contributes to its pathogenesis, recent years have also shown a strong risk-modulation by CNS injury induced immunosuppression, making stroke patients more susceptible to SAP. Additionally, murine models of stroke showed changes in mucociliary clearance as possible contributors to SAP. It remains unclear, whether structural integrity and mucociliary clearance of the respiratory epithel change in stroke patients, and whether these changes might contribute to the occurence of SAP.
Therefore, the investigators designed this exploratory observational pilot-study to examine the structural and functional integrity of respiratory epithel in severely affected stroke patients and correlate these findings to immune phenotyping and occurence of SAP. The investigators will conduct bronchoscopy in severely affected stroke patients to collect histological samples in order to evaluate multiple tissue predictors, as well as perform optical coherence tomography to examine ciliary kinetics in-vivo. The investigators will furthermore perform serum and plasma immune phenotyping, record occuring pneumonias and correlate these data in order to identify possible predictors of pneumonia.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Age ≥18 years
- Informed consent signed by patient or legal representatives
- Acute ischemic stroke within the past 2 weeks (except the control group)
- Indication for diagnostic or therapeutic bronchoscopy
Exclusion criteria
- Confirmed lung malignancies or specific inflammations of the lungs
- Pneumonia (only control group)
- Autoimmune diseases of respiratory system (only control group)
- Chronic inflammatory diseases of respiratory system (only control group)
- chronic obstructive pulmonary disease (COPD) and spastic diseases of respiratory system (only control group)
- Patients being committed to psychiatric institutions or prisons
Trial design
24 participants in 2 patient groups
Trial contacts and locations
Loading...
Central trial contact
Benjamin Hotter, Dr. med.; Andreas Meisel, Prof. Dr. med.
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal